GSK and Vir to supply Covid-19 antibody treatment doses to US
GlaxoSmithKline (GSK) and Vir Biotechnology have secured contracts from the US government for nearly $1bn to supply their Covid-19 antibody treatment, sotrovimab. Sotrovimab is an investigational single-dose SARS-CoV-2
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.